Dominican Republic Healthcare Product Manufacturing Regulatory Guide 2026

Healthcare product manufacturers — medical devices, pharmaceuticals, diagnostics, and personal care products with drug claims — must navigate a dual regulatory framework in the Dominican Republic: DIGEMAPS domestic oversight plus the export-market regulatory requirements of target countries (FDA for U.S.; EMA for EU; COFEPRIS for Mexico; ANVISA for Brazil). This guide consolidates the key regulatory requirements for each healthcare product category manufactured in DR for U.S. export.

Medical Devices: DIGEMAPS + FDA Dual Registration

Medical device manufacturers in DR require: (1) DIGEMAPS habilitación sanitaria (sanitary operating license) — application to DIGEMAPS’s Subdirección de Dispositivos Médicos; facility inspection by DIGEMAPS inspectors; quality system assessment (ISO 13485 review); and license issuance (60–120 day process). (2) FDA Drug Establishment Registration — annual registration at FDA.gov; payment of Medical Device User Fee (MDUFA FY2026 rate: $6,493 for large establishments, $0 for small businesses under $100M in sales); and device listing under 21 CFR Part 807. Both registrations are required simultaneously for U.S. export — FDA registration alone without DIGEMAPS license does not permit legal manufacturing in DR.

Pharmaceuticals: DIGEMAPS + FDA Drug Registration

Pharmaceutical manufacturers in DR require: DIGEMAPS Drug Manufacturing License under Law 6-97 (Pharmaceutical Products Law); facility compliance with 21 CFR Part 211 cGMP standards (DIGEMAPS inspects to FDA-equivalent standards); FDA Drug Establishment Registration (annual); and drug-specific FDA approvals — Abbreviated New Drug Application (ANDA) for generics, New Drug Application (NDA) for innovators, or OTC Monograph compliance for OTC drugs. DR pharmaceutical manufacturers exporting APIs must also comply with ICH Q7 GMP for Active Pharmaceutical Ingredients.

In Vitro Diagnostics (IVD): DIGEMAPS + FDA

IVD manufacturers face a complex regulatory landscape: FDA classifies most IVDs as medical devices (Class I–III) under 21 CFR Parts 820 and 862–866; EU MDR/IVDR reclassification has elevated many IVD products to Class C and D (requiring notified body involvement). DR DIGEMAPS registers IVDs as dispositivos médicos de diagnóstico in vitro under the general medical device registration framework. SARS-CoV-2 diagnostics experience during COVID-19 demonstrated that DR manufacturers could achieve FDA Emergency Use Authorization (EUA) and DIGEMAPS emergency authorization simultaneously — a regulatory coordination capability that strengthens DR’s position as a healthcare product manufacturing hub.

Personal Care and OTC Drug-Cosmetics

Products making drug claims (sunscreens, antiperspirants, anti-dandruff, acne treatment) require OTC drug registration under FDA’s Monograph system — DR manufacturers must comply with applicable OTC Monograph active ingredient concentrations, product formulations, and labeling requirements under 21 CFR Parts 330–358. MoCRA cosmetic registration (for non-drug cosmetics) requires FDA facility registration and product listing separate from OTC drug registration. DIGEMAPS registers both OTC drugs and cosmetics under distinct licensing categories; proper product classification (drug vs. cosmetic) is essential for correct DIGEMAPS and FDA registration pathway selection.

Import Alert and Warning Letter Risk Management

DR healthcare product manufacturers face FDA Import Alert risk if: product samples fail compliance testing at U.S. ports; FDA Form 483 inspection observations are not adequately addressed; or Warning Letters are issued for cGMP violations. Import Alert listing (red list) prevents DR-manufactured healthcare products from entering U.S. commerce until FDA releases the Alert. Maintaining FDA cGMP compliance and proactive 483 response management is critical for DR healthcare product exporters.

EGS Regulatory Strategy Support

Esco Global Strategies coordinates regulatory strategy for healthcare product manufacturers establishing DR operations, including DIGEMAPS application navigation, FDA registration support, and regulatory compliance gap analysis. Complete the EGS qualification assessment to initiate regulatory planning for your DR healthcare product manufacturing program.

Explore More: EGS Insights Hub | DR Manufacturing Sectors | Contact Our Team